Loading...
•
Jun 30, 2022
Ocugen Q2 2022 Earnings Report
Reported financial results and provided a business update.
Key Takeaways
Ocugen reported its Q2 2022 financial results, highlighting progress in its vaccine and gene therapy programs, including the ongoing Phase 2/3 clinical trial for COVAXIN™ and the completion of Cohort 1 dosing in the OCU400 gene therapy clinical trial. The company also expanded its pipeline with the addition of NeoCart®, a Phase 3-ready cell therapy platform.
Continued dosing patients in U.S. Phase 2/3 COVAXIN™ clinical trial
Completed dosing of patients in Cohort 1 of OCU400 gene therapy product candidate
Expanded product pipeline with the regenerative medicine cell therapy program NeoCart®
The Company’s cash, cash equivalents, and restricted cash totaled $115.0 million as of June 30, 2022
Ocugen
Ocugen
Forward Guidance
Ocugen believes that its current cash and cash equivalents balance will enable it to fund its operations into the second quarter of 2023.